Press Release

Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases

Paris (France), 9th May 2017 – Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EY...

Eyevensys annonce le démarrage d’une première étude clinique chez l’homme basée sur sa technologie innovante d’électrotransfert de plasmide, EyeCET

Paris, le 9 mai 2017 – Eyevensys annonce avoir traité un premier patient inclus dans l’essai clinique de EYS606, son médicament candidat pour le traitement des uvéites non infectieu...

Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development

Paris (France), 20th April 2017 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enable...

Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development

Paris (France), 11th April 2017 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that e...

Eyevensys reçoit l’autorisation de l’ANSM pour lancer la première étude clinique utilisant sa plateforme EyeCET

Paris (France), 11 Avril 2017 - Eyevensys, société de biotechnologie spécialisée dans le développement d’ EyeCET, première plateforme de thérapie génique non virale oculair...